cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Relmada Therapeutics Inc
4 own
3 watching
Current Price
$0.4
$0
(-0.97%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
102.94M
52-Week High
52-Week High
7.22300
52-Week Low
52-Week Low
0.34200001
Average Volume
Average Volume
1.24M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization102.94M
icon52-Week High7.22300
icon52-Week Low0.34200001
iconAverage Volume1.24M
iconDividend Yield--
iconP/E Ratio--
What does the Relmada Therapeutics Inc do?
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Read More
How much money does Relmada Therapeutics Inc make?
News & Events about Relmada Therapeutics Inc.
Globe Newswire
1 year ago
NEW YORK, July 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Seagate Technology...
Globe Newswire
1 year ago
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), DoubleVerify Holdings, Inc. (NYSE: DV), Sanmina Corporation (NASDAQ: SANM), and JinkoSolar ...
Globe Newswire
1 year ago
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), Seagate Technology Holdings Plc (NASDAQ: STX), Chegg, Inc. (NYSE: CHGG), and Relmada Therapeutics, ...
PR Newswire
1 year ago
RLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws RLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws PR Newswire...
PR Newswire
1 year ago
RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc. RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities...
Frequently Asked Questions
Frequently Asked Questions
What is Relmada Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Relmada Therapeutics Inc shares?
plus_minus_icon
How can I buy Relmada Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Relmada Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Relmada Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Relmada Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Relmada Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Relmada Therapeutics Inc?
plus_minus_icon
What percentage is Relmada Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Relmada Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.4
$0
(-0.97%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
IMMUNIC INC
IMMUNIC INC
$1.00
$-0.07 (-6.07 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$1.21
$-0.13 (-9.70 %)
Veru Inc
Veru Inc
$0.74
$-0.02 (-2.17 %)
Allovir Inc
Allovir Inc
$0.40
$-0.01 (-2.44 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
IMMUNIC INC
IMMUNIC INC
$1.00
$-0.07 (-6.07 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$1.21
$-0.13 (-9.70 %)
Veru Inc
Veru Inc
$0.74
$-0.02 (-2.17 %)
Allovir Inc
Allovir Inc
$0.40
$-0.01 (-2.44 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00